CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 9 enrolled
Drug / intervention
Deferasirox and deferipronedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01709032
NCT01709032Phase 2Completed
CompareCT.gov

Pilot Study of Deferasirox and Deferiprone Combination Oral Chelation for Individuals With Transfusion Dependent Thalassemia and High Iron Burden

Children's Hospital of Philadelphia·interventional·Posted Oct 17, 2012·Updated Mar 6, 2019

In Brief

A Phase 2 clinical trial evaluating Deferasirox and deferiprone for Thalassemia Major With Severe Transfusional Iron Overload. Completed, enrolled 9 participants across 2 sites.

Detailed Summary

We hypothesize that the combination treatment with deferasirox and deferiprone will be well tolerated and will result in significant improvement in cardiac and liver iron levels.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsThalassemia Major With Severe Transfusional Iron Overload
CountriesUnited States
CollaboratorsThe Cooley's Anemia Foundation,, Ann & Robert H Lurie Children's Hospital of Chicago

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedOct 17, 2012
Enrollment StartSep 1, 2012
Primary CompletionAug 1, 2015
Study CompletionAug 1, 2017
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 13.7 years ago

Interventions

Deferasirox and deferipronedrug